MedPath

To evaluate the effect of the test product on healthy human subjects.

Not Applicable
Registration Number
CTRI/2024/04/064998
Lead Sponsor
Cipla Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Age: 18 to 55 years(both inclusive) at the time of consent.

2. Sex: Healthy male and non-pregnant/non-lactating female.

3. Females of childbearing potential must have a self-reported negative urine pregnancy test.

4. Subjects with skin hydration less than 40 percentage at application site though the instrumental assessment and as per the dermatologist ( for dry skin subjects)

5.Subject is in good general health as determined by the Investigator on the basis of medical history.

6.Subjects should be willing and able to follow the study protocol to participate in the study.

7.Subject must be able to understand and provide written informed consent to participate in the study.

8.Subject is willing to refrain from vigorous physical exercise during the study period.

9.Subjects is willing not to use any other marketed product on application site during the study visit.

Exclusion Criteria

1.Subject has any known allergy to test product ingredient.

2.Presence of any chronic disease or illness in the past three months or any clinically significant on-going chronic medical illness e.g. Congestive cardiac failure, Hepatitis, Hypotensive episodes, etc.

3.Participation in any similar clinical trial within the past 90 days.

4.Currently have any allergies or chronic allergies or sensitivities to soaps, shampoos, conditioners, or any other skin care products as well as fragrances.

5.Currently using any topical medications.

6.Consume any alcoholic beverages during the days of the study.

7.Pregnant or lactating females.

8.Self-reported Positive HIV test.

9.History of Hepatitis B or C virus self-reported.

10.Have any other condition or factor that the Investigator believes may affect interpretation of the results.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. To assess the effectiveness of the test product in terms of change in skin barrier repair using Tewameter TM Hex. <br/ ><br>2.To assess the effectiveness of the test product in terms of change in skin hydration using MoisturemeterEpiD/ Corneometer CM 825. <br/ ><br>3. To assess the effectiveness of the test product in terms of change in skin texture using MoisturemeterEpiD/ Corneometer CM 825. <br/ ><br>4.To assess the effectiveness of the test product in terms of change in skin dryness, redness, smoothness, roughness, itchiness, and scaliness at application site by dermatologist and dermatologist trained evaluator.Timepoint: Baseline before application of the test product to after application at T0 (20 mins), T1 (01 hrs), and T2 (12 hrs) on Day 01, T24 hrs on Day 2, and 28 Days post usage.
Secondary Outcome Measures
NameTimeMethod
1.To evaluate the efficacy of the test product in terms of subjective product perception questionnaire using 9-point hedonic scale. <br/ ><br>2. To assess the safety of the test product in terms of adverse events reported by subjects or assessed by the InvestigatorTimepoint: Baseline before application of the test product to after application at T0 (20 mins), T1 (01 hrs), and T2 (12 hrs) on Day 01, T24 hrs on Day 2, and 28 Days.
© Copyright 2025. All Rights Reserved by MedPath